| Name | Components | Example of uses, and other notes | 
| 7+3, also known as DA or DAC in case of daunorubicin, or IA or IAC in case of idarubicin use | 
7 days of Ara-C (cytarabine) plus 3 days of an anthracycline antibiotic, either daunorubicin (DA or DAC variant) or idarubicin (IA or IAC variant) | 
Acute myelogenous leukemia, excluding acute promyelocytic leukemia | 
| ABVD | 
doxorubicin (Adriamycin), bleomycin, vinblastine, dacarbazine | 
Hodgkin's lymphoma | 
| AC | 
doxorubicin (Adriamycin), cyclophosphamide | 
breast cancer | 
| BACOD | 
bleomycin, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), dexamethasone | 
Non-Hodgkin lymphomas | 
| BEACOPP | 
bleomycin, etoposide, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine, prednisone | 
Hodgkin's lymphoma | 
| BEP | 
bleomycin, etoposide, platinum agent | 
testicular cancer, germ cell tumors | 
| CA | 
cyclophosphamide, doxorubicin (Adriamycin) (same as AC) | 
breast cancer | 
| CAF | 
cyclophosphamide, doxorubicin (Adriamycin), fluorouracil (5-FU) | 
breast cancer | 
| CAPOX or XELOX | 
capecitabine and oxaliplatin | 
colorectal cancer | 
| CAV | 
cyclophosphamide, doxorubicin (Adriamycin), vincristine | 
lung cancer | 
| CBV | 
cyclophosphamide, BCNU (carmustine), VP-16 (etoposide) | 
lymphoma | 
| CHOEP | 
cyclophosphamide, hydroxydaunorubicin (doxorubicin), etoposide, vincristine (Oncovin), prednisone | 
Non-Hodgkin lymphomas | 
| CEPP | 
cyclophosphamide, etoposide, procarbazine, prednisone | 
Non-Hodgkin Lymphomas | 
| ChlVPP/EVA | 
chlorambucil, vincristine (Oncovin), procarbazine, prednisone, etoposide, vinblastine, doxorubicin (Adriamycin) | 
Hodgkin's lymphoma | 
| CHOP | 
cyclophosphamide, hydroxydaunorubicin (doxorubicin), vincristine (Oncovin), prednisone | 
non-Hodgkin lymphoma | 
| CHOP-R or R-CHOP | 
CHOP + rituximab | 
B cell non-Hodgkin lymphoma | 
| ClaPD | 
clarithromycin, pomalidomide, dexamethasone | 
multiple myeloma | 
| CMF | 
cyclophosphamide, methotrexate, fluorouracil (5-FU) | 
breast cancer | 
| CMV | 
cisplatin, methotrexate, vinblastine | 
transitional bladder carcinoma | 
| COP or CVP | 
cyclophosphamide, Oncovin (vincristine), prednisone | 
non-Hodgkin lymphoma in patients with history of cardiovascular disease | 
| COPP | 
cyclophosphamide, Oncovin (vincristine), procarbazine, prednisone | 
Hodgkin's lymphoma | 
| CT or TC | 
docetaxel (Taxotere), cyclophosphamide | 
breast cancer | 
| CTD | 
cyclophosphamide, thalidomide, dexamethasone | 
AL amyloidosis | 
| CVAD and Hyper-CVAD | 
cyclophosphamide, vincristine, doxorubicin (Adriamycin), dexamethasone | 
aggressive non-Hodgkin lymphoma, lymphoblastic lymphoma, some forms of leukemia | 
| CVE | 
carboplatin, vincristine, etoposide | 
retinoblastoma | 
| CYBORD | 
cyclophosphamide, bortezomib, dexamethasone | 
multiple myeloma, AL amyloidosis | 
| DA or DAC | 
daunorubicin x 3 days plus ara-C (cytarabine) x 7 days, a variant of 7+3 regimen | 
Acute myeloid leukemia, excluding acute promyelocytic leukemia | 
| DAT | 
daunorubicin, cytarabine (ara-C), tioguanine | 
Acute myeloid leukemia | 
| DCEP | 
dexamethasone, cyclophosphamide, etoposide, platinum agent | 
relapsed or refractory multiple myeloma | 
| DHAP | 
dexamethasone (a steroid hormone), cytarabine (ara-C), platinum agent | 
Non-Hodgkin lymphomas | 
| DHAP-R or R-DHAP | 
dexamethasone (a steroid hormone), cytarabine (ara-C), platinum agent plus rituximab | 
Non-Hodgkin lymphomas | 
| DICE | 
dexamethasone, ifosfamide, cisplatin, etoposide (VP-16) | 
aggressive relapsed lymphomas, progressive neuroblastoma | 
| DT-PACE | 
dexamethasone, thalidomide, platinum agent, doxorubicin (Adriamycin), cyclophosphamide, etoposide | 
multiple myeloma | 
| EC | 
epirubicin, cyclophosphamide | 
breast cancer | 
| ECF (MAGIC) | 
epirubicin, cisplatin, fluorouracil (5-FU) | 
gastric cancer and cancer of the esophagogastric junction (Siewert classification III) | 
| EOX | 
epirubicin, oxaliplatin, capecitabine | 
esophageal Cancer, gastric Cancer | 
| EP | 
etoposide, platinum agent | 
testicular cancer, germ cell tumors | 
| EPOCH | 
etoposide, prednisone, vincristine (Oncovin), cyclophosphamide, and hydroxydaunorubicin | 
Non-Hodgkin lymphomas | 
| EPOCH-R or R-EPOCH | 
etoposide, prednisone, vincristine (Oncovin), cyclophosphamide, and hydroxydaunorubicin plus rituximab | 
B cell Non-Hodgkin lymphomas | 
| ESHAP | 
etoposide, methylprednisolone (a steroid hormone), cytarabine (ara-C), platinum agent | 
Non-Hodgkin lymphoma | 
| ESHAP-R or R-ESHAP | 
etoposide, methylprednisolone (a steroid hormone), cytarabine (ara-C), platinum agent plus rituximab | 
Non-Hodgkin lymphoma | 
| FAM | 
fluorouracil, doxorubicin (Adriamycin), mitomycin | 
gastric cancer | 
| FAMTX | 
fluorouracil, doxorubicin (Adriamycin), methotrexate | 
gastric cancer | 
| FCM or FMC | 
fludarabine, cyclophosphamide, mitoxantrone | 
B cell non-Hodgkin lymphoma | 
| FCM-R or R-FCM or R-FMC or FMC-R | 
fludarabine, cyclophosphamide, mitoxantrone plus rituximab | 
B cell non-Hodgkin lymphoma | 
| FCR | 
fludarabine, cyclophosphamide, rituximab | 
B cell non-Hodgkin lymphoma | 
| FM | 
fludarabine, mitoxantrone | 
B cell non-Hodgkin lymphoma | 
| FM-R or R-FM or RFM or FMR | 
fludarabine, mitoxantrone, and rituximab | 
B cell non-Hodgkin lymphoma | 
| FEC | 
fluorouracil (5-FU), epirubicin, cyclophosphamide | 
breast cancer | 
| FEC-T | 
fluorouracil (5-FU), epirubicin, cyclophosphamide together, followed by docetaxel (Taxotere) | 
breast cancer | 
| FL (also known as Mayo) | 
fluorouracil (5-FU), leucovorin (folinic acid) | 
colorectal cancer | 
| FLAG | 
fludarabine, cytarabine, G-CSF | 
relapsed or refractory acute myelogenous leukemia | 
| FLAG-Ida or FLAG-IDA or IDA-FLAG or Ida-FLAG | 
fludarabine, cytarabine, idarubicin, G-CSF | 
relapsed or refractory acute myelogenous leukemia | 
| FLAG-Mito or FLAG-MITO or Mito-FLAG or MITO-FLAG or FLANG[citation needed] | 
mitoxantrone, fludarabine, cytarabine, G-CSF | 
relapsed or refractory acute myelogenous leukemia | 
| FLAMSA | 
fludarabine, cytarabine, amsacrine | 
myelodysplastic syndrome, acute myeloid leukemia | 
| FLAMSA-BU or FLAMSA-Bu | 
fludarabine, cytarabine, amsacrine, busulfan | 
myelodysplastic syndrome, acute myeloid leukemia | 
| FLAMSA-MEL or FLAMSA-Mel | 
fludarabine, cytarabine, amsacrine, melphalan | 
myelodysplastic syndrome, acute myeloid leukemia | 
| FLOT | 
fluorouracil (5-FU), leucovorin (folinic acid), oxaliplatin, docetaxel | 
esophageal cancer, gastric cancer | 
| FOLFIRI | 
fluorouracil (5-FU), leucovorin (folinic acid), irinotecan | 
colorectal cancer | 
| FOLFIRINOX | 
fluorouracil (5-FU), leucovorin (folinic acid), irinotecan, oxaliplatin | 
pancreatic cancer | 
| FOLFOX | 
fluorouracil (5-FU), leucovorin (folinic acid), oxaliplatin | 
colorectal cancer | 
| GC | 
gemcitabine, cisplatin gemcitabine, dexamethasone, and cisplatin | 
bladder cancer | 
| GDP | 
gemcitabine, dexamethasone, cisplatin | 
Non-Hodgkin lymphomas and Hodgkin lymphoma | 
| GemOx or GEMOX | 
gemcitabine, oxaliplatin | 
Non-Hodgkin lymphomas | 
| GVD | 
gemcitabine, vinorelbine, pegylated liposomal doxorubicin | 
Hodgkin lymphoma | 
| GemOx-R or GEMOX-R or R-GemOx or R-GEMOX | 
gemcitabine, oxaliplatin, rituximab | 
Non-Hodgkin lymphomas | 
| IA or IAC | 
idarubicin x 3 days plus Ara-C (cytarabine) x 7 days, a variant of classical 7+3 regimen | 
Acute myelogenous leukemia, excluding acute promyelocytic leukemia | 
| ICE | 
ifosfamide, carboplatin, etoposide (VP-16) | 
aggressive lymphomas, progressive neuroblastoma | 
| ICE-R or R-ICE or RICE | 
ICE + rituximab | 
high-risk progressive or recurrent lymphomas | 
| IFL | 
irinotecan, leucovorin (folinic acid), fluorouracil | 
colorectal cancer | 
| IVA | 
ifosfamide, vincristine, actinomycin D | 
rhabdomyosarcoma | 
| MAP or MAPIE | 
Doxorubicin (Adriamycin), Cisplatin, Methotrexate, Ifosfamide (Ifex), Etoposide (Vepesid) | 
Bone cancer, Osteosarcoma | 
| m-BACOD | 
methotrexate, bleomycin, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), dexamethasone | 
non-Hodgkin lymphoma | 
| MACOP-B | 
methotrexate, leucovorin (folinic acid), doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), prednisone, bleomycin | 
non-Hodgkin lymphoma | 
| MAID | 
mesna, doxorubicin, ifosfamide, dacarbazine | 
soft-tissue sarcoma | 
| MINE | 
mesna, ifosfamide, novantrone, etoposide | 
Non-Hodgkin lymphomas and Hodgkin lymphoma in relapse or refractory cases | 
| MINE-R or R-MINE | 
mesna, ifosfamide, novantrone, etoposide plus rituximab | 
Non-Hodgkin lymphomas and Hodgkin lymphoma in relapse or refractory cases | 
| MMM | 
mitomycin, methotrexate, mitoxantrone | 
breast cancer | 
| MOPP | 
mechlorethamine, vincristine (Oncovin), procarbazine, prednisone | 
Hodgkin's lymphoma | 
| MVAC | 
methotrexate, vinblastine, doxorubicin (Adriamycin), cisplatin | 
advanced bladder cancer[4] | 
| MVP | 
mitomycin, vindesine, cisplatin | 
lung cancer and mesothelioma | 
| NP | 
cisplatin, vinorelbine | 
non-small cell lung carcinoma | 
| PACE | 
platinum agent, doxorubicin (Adriamycin), cyclophosphamide, etoposide | 
 | 
| PCV | 
Procarbazine, CCNU (lomustine), vincristine | 
brain tumors | 
| PEB | 
cisplatin, etoposide, bleomycin | 
non-seminomatous germ cell tumors | 
| PEI | 
cisplatin, etoposide, ifosfamide | 
small-cell lung carcinoma | 
| platin + taxane[5] | 
cisplatin/carboplatin, paclitaxel/docetaxel | 
ovarian cancer | 
| POMP | 
6-mercaptopurine (Purinethol), vincristine (Oncovin), methotrexate, and prednisone | 
acute adult leukemia[6] | 
| ProMACE-MOPP | 
methotrexate, doxorubicin (Adriamycin), cyclophosphamide, etoposide + MOPP | 
non-Hodgkin lymphoma | 
| ProMACE-CytaBOM | 
prednisone, doxorubicin (Adriamycin), cyclophosphamide, etoposide, cytarabine, bleomycin, vincristine (Oncovin), methotrexate, leucovorin | 
non-Hodgkin lymphoma | 
| RdC | 
lenalidomide (Revlimid), dexamethasone, cyclophosphamide | 
AL amyloidosis | 
| R-Benda | 
rituximab + bendamustine | 
follicular lymphoma and MALT lymphoma[7] | 
| R-DHAP or DHAP-R | 
rituximab + DHAP; that is, rituximab, dexamethasone (a steroid hormone), cytarabine (ara-C), platinum agent | 
relapsed non-Hodgkin's lymphoma and Hodgkin's lymphoma | 
| R-FCM or FCM-R | 
rituximab + FCM; that is, rituximab, fludarabine, cyclophosphamide, mitoxantrone | 
B cell non-Hodgkin lymphoma | 
| R-ICE or ICE-R or RICE | 
rituximab + ICE; that is, rituximab, ifosfamide, carboplatin, etoposide | 
high-risk progressive or recurrent lymphomas | 
| RVD | 
lenalidomide (Revlimid), bortezomib, dexamethasone | 
 | 
| Stanford V | 
doxorubicin (Adriamycin), mechlorethamine, bleomycin, vinblastine, vincristine, etoposide, prednisone | 
Hodgkin lymphoma | 
| TAC or ACT | 
docetaxel (Taxotere) or paclitaxel (Taxol), doxorubicin (Adriamycin), cyclophosphamide | 
breast cancer ("TAC" can also refer to tetracaine-adrenaline-cocaine, used as local anesthetic) | 
| TAD | 
tioguanine, cytarabine (ara-C), daunorubicin | 
acute myeloid leukemia | 
| TC or CT | 
docetaxel (Taxotere), cyclophosphamide | 
breast cancer | 
| TCH | 
docetaxel (Taxotere), carboplatin, trastuzumab (Herceptin) | 
breast cancer with positive HER2/neu receptor | 
| TCHP | 
docetaxel (Taxotere), carboplatin, trastuzumab (Herceptin), pertuzumab (Perjeta) | 
breast cancer with positive HER2/neu receptor | 
| Thal/Dex | 
thalidomide, dexamethasone | 
multiple myeloma | 
| TIP | 
paclitaxel (Taxol), ifosfamide, platinum agent cisplatin (Platinol) | 
testicular cancer, germ cell tumors in salvage therapy | 
| EE-4A | 
vincristine, actinomycin[8] | 
Wilms' tumor[8] | 
| DD-4A | 
vincristine, actinomycin, doxorubicin (Adriamycin)[8] | 
Wilms' tumor[8] | 
| VABCD | 
vinblastine, doxorubicin (Adriamycin), bleomycin, lomustine (CeeNU), dacarbazine | 
MOPP refractory Hodgkin's Lymphoma | 
| VAC | 
vincristine, actinomycin, cyclophosphamide | 
rhabdomyosarcoma | 
| VAD | 
vincristine, doxorubicin (Adriamycin), dexamethasone | 
multiple myeloma | 
| VAMP | 
one of 3 combinations of vincristine and others | 
Hodgkin's lymphoma, leukemia, multiple myeloma | 
| Regimen I | 
vincristine, doxorubicin (Adriamycin), etoposide, cyclophosphamide | 
Wilms' tumor[8] | 
| VAPEC-B | 
vincristine, doxorubicin (Adriamycin), prednisone, etoposide, cyclophosphamide, bleomycin | 
Hodgkin's lymphoma | 
| VDC-IE | 
vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide | 
Ewing's sarcoma | 
| VD-PACE | 
bortezomib, dexamethasone plus platinum agent, doxorubicin (Adriamycin), cyclophosphamide, etoposide | 
multiple myeloma | 
| VIFUP | 
vinorelbine, cisplatin, fluorouracil | 
locally advanced/metastatic breast cancer | 
| VIP | 
vinblastine, ifosfamide, platinum agent, (etoposide (VP-16) may substitute for vinblastine, making a regimen sometimes referred to as VIP-16)[9][10] | 
testicular cancer, germ cell tumors | 
| VTD-PACE | 
bortezomib (Velcade), thalidomide, dexamethasone plus platinum agent, doxorubicin (Adriamycin), cyclophosphamide, etoposide | 
multiple myeloma | 
| V-DCEP | 
bortezomib (Velcade), dexamethasone, cyclophosphamide, etoposide, platinum agent | 
relapsed or refractory multiple myeloma |